DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR AMELUZ

« Back to Dashboard

Clinical Trials for Ameluz

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT01893203	Daylight-PDT for AKs: Comparing Two Photosensitizers (BF-200 ALA and MAL)	Completed	Joint Authority for Päijät-Häme Social and Health Care	Phase 4	The aim of the study is to compare the efficacy of two photosensitizers, methyl-aminolaevulinate (MAL) and 5-aminolaevulinic nanoemulsion (BF-200 ALA) in the treatment of facial actinic keratosis. We use randomized, double-blinded prospective study design. The efficacy will be assessed clinically, histopathologically and immunohistochemically.
NCT01966120	Safety and Efficacy Study for the Field-directed Treatment of Actinic Keratosis (AK) With Photodynamic Therapy (PDT)	Completed	Biofrontera Bioscience GmbH	Phase 3	The purpose of this study is to evaluate the safety and efficacy of BF-200 ALA (Ameluz) versus placebo in the field-directed treatment of mild to moderate actinic keratosis with photodynamic therapy (PDT) when using the BF-RhodoLED lamp.
NCT02144077	Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy	Active, not recruiting	Accovion GmbH	Phase 3	The aim of this study is to test the effectiveness and safety of the medicine Ameluz®, used with photodynamic therapy (PDT), to treat thin, non-aggressive rodent ulcer.
NCT02144077	Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy	Active, not recruiting	Biofrontera Bioscience GmbH	Phase 3	The aim of this study is to test the effectiveness and safety of the medicine Ameluz®, used with photodynamic therapy (PDT), to treat thin, non-aggressive rodent ulcer.
NCT02464709	Daylight PDT for Actinic Keratoses: a Multicentre Study Comparing Two Photosensitizers (BF-200 ALA Versus MAL)	Recruiting	Päijänne Tavastia Central Hospital	Phase 4	This study compares two photosensitizing creams' BF-200 ALA's (aminolevulinic acid, Ameluz®) and MAL's (methyl 5-aminolevulinate, Metvix®) efficacy on actinic keratoses in natural daylight photodynamic therapy (NDL-PDT). The participants' facial skin or scalp will be randomized in two sides and one side is treated with BF-200 ALA and the other side with MAL. Result of the treatment is assessed with clinical examination 12 months after treatment. The investigators will also compare delayed skin reactions after treatment and cost-effectiveness of both photosensitizer creams.

Clinical Trial Conditions for Ameluz

Condition Name

Condition Name for Ameluz
Intervention	Trials
Actinic Keratosis	5
Refractory Mycosis Fungoides	1
Natural Daylight Photodynamic Therapy	1
Multiple Actinic Keratoses	1

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Ameluz
Intervention	Trials
Keratosis, Actinic	6
Keratosis	6
Mycosis Fungoides	1
Mycoses	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Ameluz

Trials by Country

Trials by Country for Ameluz
Location	Trials
Finland	3
Germany	2
United States	1

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Ameluz
Location	Trials
Arizona	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Ameluz

Clinical Trial Phase

Clinical Trial Phase for Ameluz
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	4
Phase 2	2

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Ameluz
Clinical Trial Phase	Trials
Completed	5
Recruiting	2
Not yet recruiting	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Ameluz

Sponsor Name

Sponsor Name for Ameluz
Sponsor	Trials
Biofrontera Bioscience GmbH	5
Joint Authority for Päijät-Häme Social and Health Care	3
University of Tampere	2

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Ameluz
Sponsor	Trials
Other	11
Industry	7
NIH	1

Export unavailable in trial.
Subscribe for complete access.